1. Introduction {#s0005}
===============

The human body harbors on average 10--100 trillion microbes, which is more than ten times the estimated number of human cells \[[@bb0005]\]. The majority of these microbial cells reside in the gastrointestinal (GI) tract and this complex community of microorganisms in the GI tract is termed the intestinal microbiota. The historical view that the gut microbiota is largely pathogenic has undergone a paradigm shift. Over the past few decades, the importance of the commensal microbiota to human health and well-being has become increasingly evident, as the impact of a healthy and diverse intestinal microbiota on metabolic activities, the immune system and homeostasis of the intestine has become more clear \[[@bb0010]\]. Furthermore, it has been shown that the gut microbiota influences the gut-brain axis, affecting brain function and development, and to confer colonization resistance against pathogenic bacteria \[[@bb0015],[@bb0020]\].

Dysbiosis of the intestinal microbiota is defined as decreased bacterial diversity or a shift in bacterial species compared to a healthy control, e.g. a decrease in butyrate producers \[[@bb0025]\]. Many studies have shown that this dysbiosis is implicated in the development of a wide range of diseases ([Fig. 1](#f0005){ref-type="fig"}) \[[@bb0025],[@bb0030]\]. However, for most diseases it is currently unknown whether the changes in microbiota are causally related to the pathophysiology or merely a consequence of the disease. For *Clostridioides difficile* infection (CDI), there is a clear causal relationship with disease phenotype. For other diseases such as obesity and metabolic disease, a causal relationship still needs to be clarified \[[@bb0035]\]. In both scenarios, however, modulation of the intestinal microbiota to restore a balanced and diverse microbiota might hold merit to treat or prevent microbiome-related disease.Fig. 1associations between the intestinal microbiome and disease. At this moment, for most diseases it is not known whether the microbiota is causally related or merely a result of the pathophysiology. Abbreviations: NAFLD = nonalcoholic fatty liver disease, NASH = nonalcoholic steatohepatitis \[[@bb0030],[@bb0040],[@bb0510]\].Fig. 1

Fecal microbiota transplantation (FMT), also called "feces transplantation", "human intestinal microbiota transfer" and "fecal bacteriotherapy", is the transfer of the fecal microbiota from a healthy, screened donor to a recipient \[[@bb0040]\]. FMT aims to restore a disrupted microbiota and amend imbalances through establishment of a stable, complex microbiota. The earliest documented administration of a fecal suspension was by the traditional Chinese doctor Ge Hong in the 4th century \[[@bb0045]\]. He used so-called 'yellow soup' as a treatment for food poisoning and severe diarrhea. However, it wasn\'t until the 16th century that another Chinese doctor named Li Shizhen recorded a range of fecal preparations for effective treatment of GI-diseases, such as constipation, fever, vomiting and pain. Subsequently during World War II, African Bedouins advised German soldiers stationed in Africa to consume fresh camel feces as a treatment for bacterial dysentery \[[@bb0050]\]. Although the potential health benefits of microbes were already mentioned by Metchnikoff in 1907, it wasn\'t until 1958 that fecal enemas were first described for the treatment of pseudomembranous enterocolitis by Dr. Ben Eiseman, an American surgeon \[[@bb0055]\]. Thereafter, a plethora of articles on the potential of FMT to treat recurrent CDI (rCDI) have been written. In this review, the potential of FMT beyond treatment of CDI and the current evidence in support of FMT as a therapeutic approach will be discussed.

2. *Clostridioides difficile* infection {#s0010}
=======================================

Currently, most clinical experience with FMT is derived from the treatment of CDI, in particular recurrent or refractory infections \[[@bb0060]\]. Over the past decades, the incidence of CDI has risen, while the success rate of prolonged anti-microbial therapy is low (20--30% resolution rate) \[[@bb0065]\]. FMT has emerged as an important treatment option for rCDI with high resolution rates (up to 90%) \[[@bb0065], [@bb0070], [@bb0075]\]. Over 100 case reports and clinical trials on the treatment of rCDI with FMT have been published to date; most report high resolution rates of *C. difficile* associated diarrhea. The first randomized controlled clinical trial (RCT) for FMT in CDI was performed in the Netherlands by *Van Nood* et al. In this study, authors observed a primary and cumulative resolution of 81% and 94% after one and two FMTs, respectively, compared to 31% after a vancomycin regimen \[[@bb0080]\].

Subsequently, the number of RCTs addressing the use of healthy donor (allogenic) FMT to treat rCDI has increased. In several publications, FMT via colonoscopy has been shown to be superior to fidaxomicin, vancomycin and autologous FMT \[[@bb0085], [@bb0090], [@bb0095]\]. The cumulative resolution rate after FMT via colonoscopy was over 90% compared to 42% for fidaxomicin, \<30% for vancomycin and 63% for autologous FMT \[[@bb0085], [@bb0090], [@bb0095]\]. Comparison of nasogastric and colonoscopic administration of a freeze-thawed fecal suspension could not demonstrate a significant difference in resolution rate (both 90%), although the patient groups in this RCT were fairly small \[[@bb0100]\]. One RCT showed that freeze-thawed feces was as effective as fresh feces, both administrated via enema, with resolution rates of 75% and 70% respectively \[[@bb0105]\]. In contrast, another RCT reported higher resolution rates with fresh FMT via colonoscopy compared to freeze-thawed and lyophilized FMT via colonoscopy, with resolution rates of 100%, 83% and 78%, respectively \[[@bb0110]\]. However, two RCTs found oral FMT capsules with either frozen or lyophilized fecal microbiota to be as effective as FMT via enema or colonoscopy, with resolution rates around 90% \[[@bb0115],[@bb0120]\]. Recently, two small pilot RCTs evaluated the efficacy of FMT for primary CDI instead of rCDI with mixed results \[[@bb0125],[@bb0130]\]. One study observed a higher primary resolution with FMT compared to metronidazole, while vancomycin performed better than FMT in the second study \[[@bb0125],[@bb0130]\].

Several meta-analyses have confirmed the superiority of FMT over standard antibiotic treatment and indicated that FMT is a safe treatment for patients with rCDI \[[@bb0075],[@bb0135],[@bb0140]\]. In addition, colonoscopic delivery of FMT was associated with higher resolution rates, while duodenal infusion, enema and fecal amount \< 50 g were associated with lower resolution rates \[[@bb0145]\]. Cost-effectiveness analyses have shown that FMT by colonoscopy (or enema, if colonoscopy is unavailable) is cost-effective, as the FMT procedure is relatively cheap and has a high efficacy \[[@bb0150],[@bb0155]\]. The above findings have established FMT as an evidence-based treatment option for rCDI, which has been adopted by the European Society for Microbiology and Infectious disease (ESCMID) and the American College of Gastroenterology (ACG) (see [Table 1](#t0005){ref-type="table"}) \[[@bb0160],[@bb0165]\].Table 1current and potential indications for fecal microbiota transplantation.Table 1Current indicationStudiesQuality of EvidenceOutcomeRecurrent *Clostridioides difficile* infection\>10 RCTs \[[@bb0080], [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105], [@bb0110], [@bb0115], [@bb0120], [@bb0125], [@bb0130]\]\
Meta-analyses \[[@bb0075],[@bb0135], [@bb0140], [@bb0145]\]HighHighly effective, with resolution rates around 90%Potential future indicationGastrointestinal disorders -Ulcerative colitis4 RCTs \[[@bb0170],[@bb0185], [@bb0190], [@bb0195]\]\
Meta-analyses \[[@bb0180],[@bb0200]\]ModerateClinical remission around 36--37% -Crohn\'s diseaseCohort studies \[[@bb0210], [@bb0215], [@bb0220]\]\
Meta-analyses \[[@bb0180]\]LowClinical remission around 50--57%; decrease over time -Irritable bowel syndrome2 RCTs \[[@bb0235],[@bb0240]\]LowMixed results -Slow-transit constipation1 RCT \[[@bb0245]\]LowClinical remission around 37%; decrease over time -Antibiotic resistant bacteriaCohort studies \[[@bb0265], [@bb0270], [@bb0275], [@bb0280], [@bb0285]\] open-label RCT \[[@bb0290]\]LowPromising results on decolonization of ESBL-producers, VREs and CREs  Metabolic disorders -Metabolic syndrome2 RCTs \[[@bb0305],[@bb0310]\]LowIncreased insulin sensitivity, but no effect on clinical endpoints -Cardiovascular disease1 RCT \[[@bb0340]\]LowEnrichment of SCFA-producers, but no clinical effect  Neuropsychiatric disorders -Hepatic encephalopathy1 RCT \[[@bb0350]\]LowNo new episodes of HE and fewer SAE\'s -Autism spectrum disorderCohort study \[[@bb0370]\]LowDecrease in gastrointestinal and neurologic symptoms  Immunologic disorders -Graft-versus-host diseaseCohort study \[[@bb0430]\]LowOverall survival and progression-free survival of 85%[^1]

3. Gastrointestinal disorders {#s0015}
=============================

3.1. Inflammatory bowel disease {#s0020}
-------------------------------

Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn\'s disease (CD). Both are characterized by recurring inflammation of the intestine. While UC is restricted to the large intestine, CD can affect the entire gastrointestinal tract. Both pathologies have been linked to dysbiosis of the gut microbiota, with a decreased diversity and decreases in *Bacteroidetes* and *Firmicutes* \[[@bb0170]\]. However, it remains unclear whether these shifts are a cause or a consequence of IBD. Some animal studies support a role for the gut microbiota in the pathogenesis of IBD, demonstrating that intestinal exposure to colitogenic microbiota induced spontaneous colitis \[[@bb0175]\]. Based on these findings, restoration of the gut microbiota through FMT has been explored as a treatment for IBD in several clinical trials.

3.2. Ulcerative colitis {#s0025}
-----------------------

Promising case reports and uncontrolled observational cohort studies have been published on the treatment of IBD with FMT, although the response rate to FMT is lower compared to rCDI. Of these studies, 53 were summarized in a systematic review, demonstrating clinical remission in 201/555 (36%) of UC, 42/83 (51%) of CD and 5/23 (22%) of pouchitis patients after FMT \[[@bb0180]\]. To date, four RCTs on the treatment of UC using FMT have been published, all showing promising results \[[@bb0170],[@bb0185], [@bb0190], [@bb0195]\]. These results were pooled in a recent Cochrane meta-analysis, which demonstrated a significantly higher clinical remission at eight weeks in the FMT arm compared to the control arm, with 52/140 (37%) and 24/137 (18%) patients achieving remission, respectively \[[@bb0200]\]. Serious adverse events and adverse events did not significantly differ between groups. Importantly, methodology, FMT strategies and primary endpoints varied considerably among the RCTs. This exemplifies the necessity of additional dedicated studies.

Some studies indicated that the efficacy of a fecal transplant differed between transplant donors. These observations gave rise to the concept of super donors and highlight the importance of careful donor selection \[[@bb0185],[@bb0190]\]. Furthermore, an enrichment in *Eubacterium hallii* and *Roseburia inulivorans* with increased levels of short-chain fatty acids and secondary bile acids was consistently found in patients in remission after FMT \[[@bb0205]\]. In addition, in patients that did not achieve remission, an enrichment in *Fusobacterium gonidiaformans*, *Sutterella wadsworthensis*, and *Escherichia* species was observed, characterized by increased levels of heme and lipopolysaccharide biosynthesis.

3.3. Crohn\'s disease {#s0030}
---------------------

Evidence for FMT to treat CD is sparse and to date no RCTs have been published. In a meta-analysis of 11 uncontrolled observational cohort studies and case series in CD, 42/83 (51%) patients achieved clinical remission \[[@bb0180]\]. A prospective study observed clinical remission in 13/25 (52%) CD patients three months after FMT, which decreased to 5/22 (23%) 18 months after FMT \[[@bb0210]\]. Another study demonstrated that a second FMT, administered within 4 months after the first FMT, maintained the clinical benefits of the first FMT \[[@bb0215]\]. The largest prospective cohort study published to this day found a clinical remission in 79/139 (57%) patients one month after FMT and observed mild adverse events in 14% of patients one month after FMT \[[@bb0220]\]. However, the potential of FMT to treat CD is still uncertain and well-designed controlled studies addressing this question are needed. Compared to UC, CD is a more heterogeneous disease and it might be necessary to focus on specific disease phenotypes, instead of a general CD population.

3.4. Functional bowel disease {#s0035}
-----------------------------

The efficacy of FMT is actively being explored in functional GI disorders, in particular irritable bowel syndrome (IBS) and chronic constipation. IBS is a chronic noninflammatory GI disorder, characterized by abdominal pain with diarrhea and/or constipation. Although the pathophysiology of IBS is not completely understood, several associations with the intestinal microbiota have been found. In line, this suggests a potential role for FMT to treat IBS \[[@bb0225],[@bb0230]\]. Two RCTs were recently published showing conflicting results. In the first study, 36/55 (65%) patients in the FMT group had relief of IBS symptoms (\>75 points reduction on IBS severity scoring system (IBS-SSS)) three months after a single FMT via colonoscopy compared to 12/28 (43%) patients in the placebo group \[[@bb0235]\]. The second study reported a larger reduction in IBS-SSS (−125·71) in the placebo group (n = 23) after three months compared to the FMT group (n = 22) that received FMT-capsules for 12 days (−52·45) \[[@bb0240]\]. Although diversity of the microbiota increased in patients receiving FMT capsules, clinical improvement of IBS symptoms was not achieved. Discrepancies in study outcomes might originate from the different FMT administration strategies or the included IBS-subtypes. Results of several ongoing RCTs (see [Fig. 2](#f0010){ref-type="fig"}) will further disentangle the therapeutic potential of FMT to treat IBS.Fig. 2overview of ongoing trials in which the efficacy of FMT is tested for a range of diseases. Only intervention studies were included that were registered as 'active', 'recruiting', 'enrolling via invitation' or 'not yet recruiting'. In addition, studies examining the effect of FMT in treating CDI were excluded, since this is out of the scope of this review. [Table 2](#t0010){ref-type="table"} gives a more detailed overview of the ongoing studies. Abbreviations: FMT = fecal microbiota transplantation, IBD = Inflammatory Bowel Disease, IBS = Irritable Bowel Syndrome, NAFLD = Non-Alcoholic Fatty Liver Disease.Fig. 2

The gut microbiota has also been implicated in the etiology of constipation. In one RCT, 60 adults with slow transit constipation (STC) received standard of care treatment (education, behavioral strategies, and oral laxatives) either with or without an additional 6 days FMT by nasoduodenal infusion \[[@bb0245]\]. After 12 weeks, clinical improvement was observed in 16/30 (53%) versus 6/30 (20%) patients and clinical cure (≥ three complete spontaneous bowel movements per week) in 11/30 (37%) versus 4/30 (13%) patients in the FMT and control group, respectively. Two prospective studies from the same group showed a decrease in clinical cure rate over time and observed higher efficacy of FMT in combination with the polysaccharide pectin in patients with STC \[[@bb0250],[@bb0255]\]. A third prospective trial reported alleviation of bloating and pain symptoms in patients with chronic intestinal pseudo-obstruction (CIPO), a serious life-threatening motility disorder \[[@bb0260]\]. Although these results are promising, the FMT treatments were quite intense and invasive, with patients receiving up to 18 nasoduodenal FMTs over three months \[[@bb0255]\]. These limitations of dosing frequency and nasal tube placement could be addressed by using FMT capsules. Furthermore, the efficacy of the fecal microbiota in the FMT can be debated as the glycerol, used to protect the microbiota from freezing, could have a laxative effect.

3.5. Antibiotic-resistant bacteria {#s0040}
----------------------------------

An increasing healthcare threat is intestinal colonization with multidrug-resistant organisms, which may cause life-threatening infections. Through direct ecological competition, FMT may potentially stimulate decolonization of antibiotic-resistant bacteria (ARBs) and increase resistance to colonization by these pathogens. This was first described in a case report where FMT was used for the successful eradication of an extended-spectrum beta-lactamase-producing (ESBL) *Escherichia coli* \[[@bb0265]\]. Thereafter, many case reports and small prospective cohort studies have been published, showing efficacy of FMT in decolonization of ESBL-producers, vancomycin-resistant *Enterococcus (VRE)*, carbapenem-resistant *Enterobacteriaceae* (CRE) and other ARBs \[[@bb0270], [@bb0275], [@bb0280], [@bb0285]\]. One open-label RCT has been published, which demonstrated decolonization of CRE or ESBL producers in 9/22 (41%) patients who received a five-day course of oral antibiotics followed by FMT compared to 5/17 (29%) patients who didn\'t receive an intervention \[[@bb0290]\]. Interestingly, two prospective studies found a higher decolonization effect of FMT in the absence of periprocedural use of antibiotics, reporting decolonization in 6/7 (79%) and 7/8 (88%) patients after FMT \[[@bb0280],[@bb0285]\]. Although the number of treated patients is small, these studies show that FMT might be an effective therapy for decolonization of antibiotic-resistant organisms from the GI-tract and more trials are currently under way to assess its safety and efficacy (see [Fig. 2](#f0010){ref-type="fig"}).

4. Metabolic disorders {#s0045}
======================

4.1. Metabolic syndrome {#s0050}
-----------------------

There has been an increasing interest in the role of the gut microbiota in metabolic diseases, as microbes play a crucial role in digestion and absorption of nutrients from the diet. Furthermore, gut bacteria produce metabolites with critical properties for host metabolism including -but not limited to- short-chain fatty acids (SCFA) and bile acids. Dysbiosis of the intestinal microbiota has been linked to an impaired mucosal barrier function, also known as a "leaky gut", a proinflammatory state and a disturbed production of signaling molecules, such as SCFAs and bile acids \[[@bb0295]\]. Animal studies suggest a causal link between the intestinal microbiota and obesity. For example, mice colonized with obesogenic microbiota were shown to have increased body fat and insulin resistance compared to mice colonized with lean donor microbiota \[[@bb0300]\]. Currently, two placebo-controlled RCTs have been published, which determined the effect of nasoduodenal FMT in obese Caucasian males with metabolic syndrome \[[@bb0305],[@bb0310]\]. Six weeks after nasoduodenal infusion of lean donor feces, insulin sensitivity was significantly increased. This coincided with an increase in butyrate-producing intestinal microbiota. Importantly, the effect on insulin sensitivity disappeared after 18 weeks and no long-term clinical effects were found. In addition, metabolic response to FMT was found to be associated with a low microbial diversity at baseline \[[@bb0310]\]. Although the mechanisms underlying the favorable effects on insulin sensitivity are yet to be determined, these studies highlight a role for the intestinal microbiota in metabolic diseases.

4.2. NAFLD and NASH {#s0055}
-------------------

Nonalcoholic fatty liver disease (NAFLD) is characterized by accumulation of fat in the liver, which may lead to inflammation and liver damage, commonly known as nonalcoholic steatohepatitis (NASH). NASH is a major cause of liver cirrhosis and liver cancer; both primary indications for liver transplantation. Differences in microbiota composition have been observed in patients with NAFLD or NASH compared to subjects with healthy liver \[[@bb0295]\]. In addition, increased intestinal permeability and a proinflammatory environment in the gut are frequently observed in NAFLD/NASH patients \[[@bb0315]\]. Although human studies are yet to be performed, studies in high-fat diet-fed mice found that FMT reduced weight gain and nonalcoholic fatty liver score \[[@bb0320]\]. To further investigate the potential of FMT in NASH there are several RCTs underway (summarized in [Fig. 2](#f0010){ref-type="fig"}), determining the efficacy of FMT compared to standard therapy in NASH related cirrhosis.

4.3. Cardiovascular disease {#s0060}
---------------------------

Accumulating evidence has implicated a role of the intestinal microbiota and microbial metabolites in the development of cardiovascular disease such as atherosclerosis and hypertension \[[@bb0325]\]. In an animal model, the introduction of a proinflammatory microbiota low in SCFA-producers enhanced systemic inflammation and accelerated atherogenesis \[[@bb0330]\]. In another study, mice with myocarditis were subjected to FMT. This resulted in reshaping of the microbiota composition and restoration of the *Bacteroidetes* population, which was accompanied by attenuation of myocarditis through reduced inflammatory infiltration of immune cells \[[@bb0335]\]. Currently, one small RCT in humans has addressed the effect of a single lean vegan-donor FMT on vascular inflammation and trimethylamine-N-Oxide (TMAO) production. TMAO is a microbial metabolite which increases atherosclerotic burden and stimulates a prothrombotic phenotype \[[@bb0340]\]. Although SCFA-producers were significantly enriched in the allogenic FMT group, no differences were detected in TMAO production or vascular inflammation at two weeks.

5. Neuropsychiatric disorders {#s0065}
=============================

5.1. Hepatic encephalopathy {#s0070}
---------------------------

Hepatic encephalopathy (HE) comprises a spectrum of neuropsychiatric abnormalities as a result of end-stage liver cirrhosis. HE has been associated with differences in the microbiota and an increased relative abundance of ammonia-producing bacteria \[[@bb0345]\]. Subsequent hyperammonemia is associated with impaired neuronal function \[[@bb0345]\]. Current treatment strategies for HE consist of lactulose supplementation and treatment with the nonabsorbable antibiotic rifaximin, which both influence the intestinal microbiota. Currently, one RCT has been published in which patients with HE were treated with a single FMT via enema in addition to standard of care treatment \[[@bb0350]\]. Fewer serious adverse events (2 versus 8) and new episodes of HE (0 versus 6) were observed in the FMT arm (n = 10) compared to the control group (n = 10) receiving solely standard of care. Furthermore, cognition and dysbiosis improved after FMT. In a small pilot study, eight patients with steroid-ineligible severe alcoholic hepatitis were treated with a nasoduodenal FMT for seven days \[[@bb0355]\]. Liver disease severity reduced and coincided with resolution of ascites and HE. Moreover, survival rate improved compared to historically matched controls. These studies show promising results and multiple clinical studies addressing the use of FMT in HE are underway (see [Fig. 2](#f0010){ref-type="fig"}).

5.2. Autism spectrum disorder {#s0075}
-----------------------------

Autism spectrum disorders (ASD) are not only characterized by impairments in social interaction and communication, but often coincide with GI symptoms such as constipation or diarrhea \[[@bb0360]\]. Experiments in ASD mouse models have mechanistically linked the gut microbiota to abnormal metabolites and behavior \[[@bb0365]\]. To this day, one open-label study has explored the effect of FMT on GI and ASD symptoms in children aged 7--16 years \[[@bb0370]\]. 18 children were placed on a two-week antibiotic regimen, a bowel lavage and either an initial rectal or oral high FMT dose, followed by a daily lower oral maintenance dose for 7--8 weeks. After FMT, both GI and ASD symptoms significantly improved, which persisted for 8 weeks after treatment. These are promising results, although the potential causal contributions of the gut microbiota to ASD remain speculative.

5.3. Multiple sclerosis {#s0080}
-----------------------

A number of studies have shown intestinal microbiota dysbiosis in patients with multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system \[[@bb0375]\]. Additionally, animal models have shown that feces from patients with MS could precipitate an MS-like autoimmune disease in mice, which suggests microbiota involvement in the pathogenesis of MS. \[[@bb0380]\] Some case reports describe improvement of neurological symptoms and disease stability after FMT, although more research is needed to determine the benefit and safety of FMT in MS. \[[@bb0385],[@bb0390]\]

6. Parkinson\'s disease {#s0085}
=======================

Also for Parkinson\'s disease (PD) intestinal dysbiosis has been reported, with decreases in *Prevotella* and butyrate-producing bacteria \[[@bb0395]\]. An observational study found a decrease in total count of gut microbiota during PD progression and changes in gut microbiota could be correlated with a rapid or slow disease progression \[[@bb0395]\]. In a mouse model, gut microbiota transplantation from donor mice with PD reduced striatal neurotransmitter release with subsequent motor impairment in healthy recipient mice \[[@bb0400]\]. Furthermore, healthy mouse donor FMT had neuroprotective effects in PD mice through suppression of neuroinflammation and reduction of TLR4/TNF-α signaling \[[@bb0400]\]. FMT could have a potential benefit in PD, but studies in humans have not been performed yet.

7. Immunologic disorders {#s0090}
========================

7.1. Graft-versus-host disease {#s0095}
------------------------------

Acute intestinal graft-versus-host disease (GVHD) is a major cause of mortality in patients that receive an allogenic hematopoietic stem cell transplantation (HCT). Standard treatment consists of immunosuppressive steroids, although some patients develop steroid-refractory GVHD for which no well-established treatment is available. Growing evidence suggests that the risk of GVHD is influenced by host-microbiota interactions and one study observed an increased mortality in recipients with a lower phylogenetic diversity \[[@bb0405]\]. In a mouse model, alterations in intestinal microbiota following HCT resulted in a decreased butyrate production, potentially contributing to a proinflammatory state of the intestine \[[@bb0410]\]. Results from several case series on FMT to treat acute steroid-refractory GVHD have shown some promise, demonstrating resolution of clinical symptoms, restoration of microbiota composition and a higher progression-free survival \[[@bb0415], [@bb0420], [@bb0425]\]. In a recent prospective open-label study, 13 patients were treated with FMT capsules to restore their intestinal microbiome diversity at a median of 27 days after HCT \[[@bb0430]\]. During a median follow-up period of 15 months after FMT, two patients developed acute GI GVHD which resulted in one death. The 12-month overall survival and progression-free survival were both 85%. Although the results of FMT in GVHD are promising, larger controlled studies are needed.

7.2. Cancer {#s0100}
-----------

Microbial dysbiosis has been extensively observed in human malignancies \[[@bb0435]\]. Several bacterial species are linked to colorectal cancer (CRC), including *Enterococcus faecalis*, *Escherichia coli* and *Bacteroides fragilis* \[[@bb0440]\]. This finding was supported by animal studies, in which the infusion of feces from patients with CRC could promote tumorigenesis in germ-free mice \[[@bb0445]\]. Although FMT has not been tested as a treatment for CRC, it has been used to increase the efficacy of immune checkpoint inhibitors (ICI). Only a minority of patients with CRC responds to ICIs, which has been linked to an abnormal gut microbiome composition \[[@bb0450]\]. Moreover, it has been shown that antibiotics inhibit the clinical benefit of ICIs \[[@bb0450]\]. It has been hypothesized that restoration of the microbiome reinforces the intestinal barrier integrity and reduces systemic inflammation \[[@bb0450]\]. When the feces from cancer patients who responded to ICIs was transplanted into germ-free mice, the antitumor effects of ICIs were ameliorated, whereas feces from non-responders failed to do so \[[@bb0450]\]. In one case-series, FMT was used to successfully treat refractory ICI-associated colitis, reconstitute the GI microbiome and increase the proportion of regulatory T-cells in the colonic mucosa \[[@bb0455]\]. These results indicate the important role of the microbiota in ICI-related toxicity and efficacy and point to a potential role for microbiota-modifying therapies, such as FMT. A recently published review by Wardill et al. extensively describes the use of FMT in supportive oncology more into depth \[[@bb0460]\].

8. Discussion & conclusion {#s0105}
==========================

Interest in FMT to treat disease has risen over the last few years and its therapeutic benefit is currently being explored for a variety of diseases. [Table 1](#t0005){ref-type="table"} provides an overview of the current and potential indications for FMT. Besides the above described disorders, the use of FMT has been described in case reports as treatment for multiple organ dysfunction syndrome, chronic pouchitis and celiac disease \[[@bb0465], [@bb0470], [@bb0475]\]. However, for most diseases it is not fully known whether the changes in microbiota are causally related to the pathophysiology, or merely a result of the disorder. If the intestinal microbiota plays a causal role in disease pathophysiology, altering the microbiota may influence its course. In most cases, however, a single microorganism is not likely to be a causal pathogen or missing beneficial microbe. Therefore, an advantage of FMT over prebiotics and probiotics is the introduction of a complete healthy gut microbiota. FMT can be used as a tool to dissect association from causality in human intervention studies by assessing the effect of the microbiota on a disease. [Fig. 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"} give an overview of currently ongoing clinical trials that study the potential of FMT as a treatment for a variety of disorders.

Currently, FMT is a non-standardized treatment which should be optimized and standardized for specific indications. This is supported by the finding of super donors, which suggests a specific bacterial composition can be more effective to treat a certain disease \[[@bb0185],[@bb0190]\]. In addition, treatment strategy and route can impact the microbiota composition and colonization, which can influence the therapeutic effect. With the development of FMT capsules, the therapy became less invasive, more standardized, and less expensive \[[@bb0480]\]. However, some microbes (or metabolites) critical for the efficacy of an FMT might not survive the processing required for capsulation. Therefore, it is important to determine the differences between fresh and processed fecal microbiota and the efficacy in particular diseases. Furthermore, optimal location of delivery and 'dose' of FMT to treat microbiota-mediated diseases are largely unknown. A small cohort study showed that capsules releasing fecal microbiota in the colon achieved a slightly higher cure rate (81%) compared to gastric release (75%) in treating patients with rCDI \[[@bb0485]\]. Delivery of microbiota to a specific area of the intestine via targeted opening of a capsule might be an interesting future approach to further investigate.

Given the variable composition of feces, FMT will probably be replaced by other microbiome-targeting therapeutics. While the knowledge of the microbiota and host-commensal interactions in dysbiotic environments increases, it is to be expected that dietary manipulation and specific alteration of key microbes will be emerging in the future. Furthermore, it appears FMT is not a one-size-fits-all therapy and needs a more personalized approach for several disorders. For instance, donors with a specific microbiota profile are more likely to provide a beneficial effect for patients with IBD \[[@bb0185],[@bb0190]\]. Other studies have shown that the microbiota profile of the recipient is predictive for the outcome of the FMT \[[@bb0310]\]. Future studies should therefore focus more on donor-recipient compatibility and suitability prior to FMT.

With the rapid increase in novel and more affordable techniques to analyze the gut microbiota, implications for a role of this 'endocrine organ' in disease development has risen exponentially. It is important to emphasize however, that besides bacteria, the microbiota consists of archaea, viruses (especially bacteriophages) and fungi. Bacteriophages, viruses that specifically infect and eliminate bacteria, were found to be 20 times more abundant than bacteria in mucosal samples \[[@bb0490]\]. Given the high number of bacteriophages in an FMT (1--10 times the number of bacteria), these viruses might be important drivers of FMT efficacy. In a small prospective study, the effect of a sterile (bacteria-free) FMT was tested in rCDI patients \[[@bb0495]\]. Although only five patients were included, all patients had resolution of their CDI-associated diarrhea. Interestingly, shifts in viral and bacterial composition towards the donor\'s microbiota profile were observed. Another prospective study observed highly individualized virus colonization patterns depending on specific donor-recipient pairings \[[@bb0500]\]. The intestinal microbiome is a complex ecosystem with many yet to be identified components likely to affect human metabolism.

In addition, there is a significant knowledge gap in the link between the (small) intestinal microbiota and disease development and progression in humans. This is in large part because the accessible, fecal microbiome is usually used to analyze the microbiome composition and associate with the disease of interest (fecal bias). The small intestinal microbiome differs significantly form the fecal microbiome \[[@bb0505]\]. Together with the fact that the small intestine plays a major role in human metabolism and disease development, it is critical to develop strategies to sample small intestinal microbiome. In line, nasoduodenal administration of FMT exposes the upper GI to a lower GI/fecal microbiome. This might be a potential drawback for diseases where the upper GI microbiota or the mucosal microbiota is the main culprit. Future research needs to investigate whether and to what extent FMT is capable of modifying the upper and mucosal microbiota.

In conclusion, FMT is a promising treatment strategy for many microbiota-related indications. However, with exception of rCDI, FMT is still experimental and should not be offered as treatment option outside of a research setting. More controlled trials are needed to assess the potential benefit of FMT compared to or in addition to standard therapy.

9. Outstanding questions {#s0110}
========================

FMT remains an unstandardized procedure and the optimal location of delivery and 'dose' of FMT to treat specific microbiota-mediated diseases remain largely unknown. Some studies show a specific microbiota profile is more effective in treating disease, while others show the microbiota profile of the recipient is predictive for the outcome of the FMT. For treating rCDI, the above appears less relevant, as high effectivity rates are observed regardless of the route, dose, processing or donor. However, FMT as a treatment for other disease comes with a smaller effect size along with a larger group of nonresponders. Further optimization and personalization of the FMT strategy might improve the outcome in diseases beyond CDI.

The gut microbiota remains a complex ecosystem with lot of unknowns and therefore, future research should focus more on other key players beside bacteria. In addition, there is a significant difference in microbiota composition throughout the GI tract and the role of each section in human metabolism and disease development is hardly understood. Therefore, it is critical to develop strategies to sample the microbiome throughout the GI tract. In line, future research needs to investigate whether and to what extent FMT is capable of modifying the upper and mucosal microbiota.Table 2Ongoing trials with fecal microbiota transplantation for indications other than CDI.Table 2IndicationNCT numberInterventionStudy designPrimary outcomePatients (n)IBD[NCT03399188](NCT03399188){#ir0005}I: FMT via colonoscopySingle group, open label trial- Clinical remission (PUCAI / Mayo score / PCDAI / CDAI) \[6 months\]100[NCT02575040](NCT02575040){#ir0010}I: FMTSingle group, open label trial- number of patients with worsened disease \[1 year\]\
- Safety: (serious) adverse events \[1 year\]60Ulcerative colitis[NCT01790061](NCT01790061){#ir0015}I: FMT via DJ\
C: standard of care treatmentControlled, open label trial- Clinical remission (Montreal score S0) \[1 year\]500[NCT03843385](NCT03843385){#ir0020}I: fecal microbiota filtrate capsules\
II: FMT capsules\
C: placebo capsules3- arm, randomized, placebo-controlled, quadruple blinded trial- Clinical remission (Mayo score) \[12 weeks\]174[NCT03483246](NCT03483246){#ir0025}I: FMT via colonoscopy\
C: sham via colonoscopyRandomized, placebo-controlled, single blinded trial- Steroid-free clinical and endoscopic remission \[12 weeks\]150[NCT03804931](NCT03804931){#ir0030}I: FMT\
C: SalineRandomized, placebo-controlled, single blinded trial- Clinical remission (Mayo score) \[12 weeks\]\
- Clinical improvement (Mayo score) \[12 weeks\]120[NCT03110289](NCT03110289){#ir0035}I: super donor FMT\
C: autologous FMTRandomized, controlled, quadruple blinded trial- Clinical remission (Mayo score) \[8 weeks\]\
- Endoscopic remission \[8 weeks\]108[NCT02291523](NCT02291523){#ir0040}I: allogenic FMT via colonoscopy\
C: autologous FMT via colonoscopyRandomized, controlled, quadruple blinded trial- Clinical remission (PUCAI) \[12 months\]101[NCT03582969](NCT03582969){#ir0045}[a](#tf0005){ref-type="table-fn"}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, triple blinded trial- Clinical remission (SCCAI) \[12 weeks\]100[NCT03561532](NCT03561532){#ir0050}I: allogenic FMT via colonoscopy\
C: autologous FMT via colonoscopyRandomized, controlled, quadruple blinded trial- Clinical and endoscopic remission \[52 weeks\]80[NCT02606032](NCT02606032){#ir0055}I: FMT + metronidazole + doxycycline + terbinafine\
C: FMTRandomized, controlled, quadruple blinded trial- Clinical and endoscopic remission \[9 weeks\]80[NCT03016780](NCT03016780){#ir0060}I: FMT\
C: SalineRandomized, placebo-controlled, open label trial- Safety: (serious) adverse events \[3 months\]60[NCT03104036](NCT03104036){#ir0065}I: FMT via enema\
C: mesalazine enemaRandomized, controlled, open label trial- Clinical remission (Mayo score) \[12 weeks\]60[NCT03006809](NCT03006809){#ir0070}I: antibiotics + FMT via colonoscopy + FMT capsules\
II: FMT via colonoscopy + FMT capsules\
III: antibiotics + FMT via colonoscopy + FMT via enema\
IV: FMT via colonoscopy + FMT via enema4-arm, randomized, controlled, open label trial- Safety: (serious) adverse events \[1 year\]\
- Clinical and endoscopic remission \[8 weeks\]40[NCT02734589](NCT02734589){#ir0075}I: FMT via colonoscopy\
II: diet for UC + FMT\
III: diet for UC3-arm, randomized, controlled, single blinded trial- Clinical remission (SCCAI) \[56 days\]34[NCT03948919](NCT03948919){#ir0080}I: low sulfur FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, quadruple blinded trial- Engraftment of sulfate reducing microbiota \[12 weeks\]20[NCT02390726](NCT02390726){#ir0085}I: FMT\
C: placebo FMTRandomized, placebo-controlled, double blinded trial- Endoscopic stage \[2 years\]\
- Biologic inflammatory markers \[2 years\]\
- Symptomatology and quality of life \[2 years\]20[NCT03949257](NCT03949257){#ir0090}I: FMT via DJSingle group, open label trial- Gut microbiome \[7 days\]20[NCT03716388](NCT03716388){#ir0095}I: FMT + mesalazine granules\
II: FMT + placebo granules\
III: mesalazine granules + placebo FMT3-arm randomized, controlled, double blinded trial- Clinical remission (Mayo score) \[14 weeks\]15Crohn\'s disease[NCT01793831](NCT01793831){#ir0100}I: FMT via DJSingle group, open label trial- Clinical remission (HBI score) \[1 year\]200[NCT03078803](NCT03078803){#ir0105}I: FMT via colonoscopy and capsules\
C: water via colonoscopy and placebo capsulesRandomized, placebo-controlled, quadruple blinded trial- Clinical and endoscopic remission \[8 weeks\]126[NCT03378167](NCT03378167){#ir0110}I: FMT via colonoscopy + FMT capsules\
C: Placebo FMTRandomized, placebo-controlled, triple blinded, crossover trial- Monthly Recruitment Rate \[30 weeks\]\
- Dropout Rate Post Enrolment \[30 weeks\]\
- Rate of Patient Protocol Adherence \[30 weeks\]\
- Safety: (serious) adverse events \[30 weeks\]45[NCT02417974](NCT02417974){#ir0115}I: FMT via colonoscopy\
C: no interventionRandomized, controlled, single blinded trial- Endoscopic recurrence after ileo-cecal resection (Rutgeert\'s score) \[6 months\]44[NCT03267238](NCT03267238){#ir0120}I: FMTSingle group, open label trial- Treatment-related adverse events (CTCAE v4.0) \[5 years\]40[NCT03747718](NCT03747718){#ir0125}I: FMT via enema\
C: placebo via enemaRandomized, placebo-controlled, triple blinded trial- Safety: (serious) adverse events \[6 months\]30[NCT03194529](NCT03194529){#ir0130}I: FMT via DJSingle group, open label trial- Safety: (serious) adverse events \[24 weeks\]10Pouchitis[NCT03524352](NCT03524352){#ir0135}I: FMT\
C: sterile salineRandomized, placebo-controlled, double blinded trial- Clinical and endoscopic relapse \[PDAI) \[106 weeks\]42[NCT03545386](NCT03545386){#ir0140}I: FMT via enema\
C: saline via enemaRandomized, placebo-controlled, triple blinded trial- Clinical remission (PDAI) \[7 weeks\]34[NCT03378921](NCT03378921){#ir0145}I: allogenic FMT via colonoscopy\
C: autologous FMT via colonoscopyRandomized, controlled, triple blinded trial- Clinical remission (PDAI) \[52 weeks\]26Microscopic colitis[NCT03275467](NCT03275467){#ir0150}I: FMT via colonoscopy + FMT via enemaSingle group, open label trial- Remission (\<3 stools/day) \[6 weeks\]10IBS[NCT03613545](NCT03613545){#ir0155}I: FMT via colonoscopy\
C: sham via colonoscopyRandomized, placebo-controlled, single blinded trial- IBS severity (IBS-SSS) \[6 months\]120[NCT03125564](NCT03125564){#ir0160}I: FMT\
C: placebo FMTRandomized, placebo-controlled, double blinded trial- Proportion of responder \[12 weeks\]90[NCT02847481](NCT02847481){#ir0165}I: FMT\
C: placebo FMTRandomized, placebo-controlled, double blinded trial- Engraftment of donor microbiota \[10 weeks\]80[NCT02857257](NCT02857257){#ir0170}I: Anaerobic cultured human intestinal microbiotaSingle group, open label trial- Symptom relief (IBS-SSS) \[4 weeks\]50[NCT03074227](NCT03074227){#ir0175}I: allogenic FMT via DJ\
C: autologous FMT via DJRandomized, controlled, quadruple blinded trial- \>50% reduction in severity and frequency of abdominal pain \[12 weeks\]30[NCT02092402](NCT02092402){#ir0180}I: allogenic FMT\
C: autologous FMTRandomized, controlled, quadruple blinded trial- Symptoms of IBS patients (GSRS-IBS) \[6 months\]17[NCT02651740](NCT02651740){#ir0185}I: Rifaximin 400 mg + FMT via DJSingle group, open label trial- Relief of IBS condition \[6 months\]10Chronic constipation[NCT03018613](NCT03018613){#ir0190}I: FMT\
C: SalineRandomized, placebo-controlled, open label trial- Safety: (serious) adverse events \[3 months\]60Antibiotic resistant organisms[NCT03061097](NCT03061097){#ir0195}I: autologous FMT via enema\
C: placebo via enemaRandomized, placebo-controlled, triple blinded trial- Safety: (serious) adverse events \[7 days\]180[NCT03643887](NCT03643887){#ir0200}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, triple blinded trial- VRE/CRE decolonization \[6 months\]90[NCT03391674](NCT03391674){#ir0205}I: FMT capsules + omeprazole\
C: no interventionRandomized, controlled, open label trial- CRE Decolonization (3 consecutive negative stool samples for CRE) \[3 months\]60[NCT03167398](NCT03167398){#ir0210}I: FMT capsules + omeprazoleSingle group, open label trial- CRE Decolonization (3 consecutive negative stool samples for CRE) \[1 month\]60[NCT03834051](NCT03834051){#ir0215}I: FMT via enemaSingle group, open label trial- Clearance of antimicrobial resistant organism \[2 years\]50[NCT03029078](NCT03029078){#ir0220}I: FMT via DJSingle group, open label trial- Intestinal colonization with CRE/VRE \[6 months\]50[NCT03802461](NCT03802461){#ir0225}I: FMT via enema\
C: standard of care treatmentRandomized, controlled, open label trial- Intestinal colonization with CRE \[3 months\]\
- Feasibility: randomization rate \[12 months\]\
- Feasibility: retention of 90% of patients \[6 months\]40[NCT03479710](NCT03479710){#ir0230}I: FMT via DJ\
C: no interventionControlled, open label trial- Intestinal colonization with CRE/VRE \[12 months\]40[NCT02472600](NCT02472600){#ir0235}I: colistin + neomycin, followed by FMT capsules or ND infusion\
C: no interventionRandomized, controlled, open label trial- Intestinal colonization with ESBL-E / CRE \[48 days\]39[NCT02922816](NCT02922816){#ir0240}I: FMT via enema\
C: no interventionRandomized, controlled, open label trial- Safety and feasibility (CTCAE v4.0) \[30 weeks\]20[NCT03527056](NCT03527056){#ir0245}I: FMT capsules\
C: no interventionControlled, open label trial- CRE decolonization \[10 days\]\
- Safety: (serious) adverse events \[10 days\]20[NCT02543866](NCT02543866){#ir0250}I: FMT via DJSingle group, open label trial- Safety and Tolerability of FMT \[1--5 years\]20[NCT02312986](NCT02312986){#ir0255}I: FMT via enemaSingle group, open label trial- Safety: (serious) adverse events \[12 months\]20[NCT02816437](NCT02816437){#ir0260}I: FMT via enemaSingle group, open label trial- Safety: (serious) adverse events \[10 months\]20[NCT03063437](NCT03063437){#ir0265}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, quadruple blinded trial- VRE decolonization \[10 days\]\
- Safety: (serious) adverse events \[10 days\]9Obesity[NCT03727321](NCT03727321){#ir0270}[a](#tf0005){ref-type="table-fn"}I: FMT + fiber supplement\
II: FMT + placebo supplement\
III: fiber supplement\
C: placebo supplement4-arm, randomized, controlled, quadruple blinded trial- Insulin resistance (HOMA-IR) \[12 weeks\]68[NCT03127696](NCT03127696){#ir0275}I: FMT + lifestyle modification program\
II: FMT\
III: lifestyle modification program3 --arm randomized, placebo-controlled, double blinded trial- 5% reduction in weight \[24 weeks\]60[NCT03273855](NCT03273855){#ir0280}I: allogenic FMT via enema\
C: autologous FMT via enemaRandomized, controlled, quadruple blinded trial- Changes in body weight \[12 months\]60[NCT02970877](NCT02970877){#ir0285}I: allogenic FMT\
C: autologous FMTRandomized, controlled, quadruple blinded trial- Insulin Resistance (HOMA-IR) \[3 months\]48[NCT03391817](NCT03391817){#ir0290}I: allogenic FMT\
C: autologous FMTRandomized, controlled, triple blinded trial- Reduction of weight \[1,5 years\]40[NCT02530385](NCT02530385){#ir0295}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, double blinded trial- Insulin resistance (HOMA-IR) \[6 weeks\]24[NCT02741518](NCT02741518){#ir0300}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, triple blinded trial- Safety: (serious) adverse events \[52 weeks\]22[NCT03789461](NCT03789461){#ir0305}I: FMTSingle group, open label trial- 10% reduction in weight \[6 weeks\]20NAFLD[NCT02868164](NCT02868164){#ir0310}I: FMT via DJ\
C: standard of care treatmentRandomized, controlled, open label trial- Adverse events complication rate in NASH \[1 year\]120[NCT02721264](NCT02721264){#ir0315}I: FMT via DJ\
C: standard of care treatmentRandomized, controlled, open label trial- Hepatic Venous Pressure Gradient \[1 year\]112[NCT03803540](NCT03803540){#ir0320}I: FMT via DJSingle group, open label trial- Histological resolution of NASH \[72 weeks\]15[NCT02469272](NCT02469272){#ir0325}I: FMT via DJSingle group, open label trial- Hepatic steatosis (by MRI) \[12 weeks\]5Alcoholic hepatitis[NCT03091010](NCT03091010){#ir0330}I: FMT via DJ\
C: prednisolone 40 mgRandomized, controlled, open label trial- Overall Survival \[3 months\]130[NCT03827772](NCT03827772){#ir0335}I: FMT via DJ\
C: standard of care treatmentControlled, open label trial- Overall Survival \[3 months\]40Liver cirrhosis & hepatic encephalopathy[NCT03796598](NCT03796598){#ir0340}I: FMT capsules + FMT enema\
II: FMT capsules + placebo enema\
III: placebo capsules + FMT enema\
C: placebo capsules + placebo enema4-arm, randomized, placebo-controlled, triple blinded trial- Serious adverse events related to FMT \[6 months\]100[NCT03363022](NCT03363022){#ir0345}I: FMT via enema\
C: placebo via enemaRandomized, placebo-controlled, double blinded trial- Survival \[21 days\]40[NCT02862249](NCT02862249){#ir0350}I: FMT via DJ\
C: placebo via DJRandomized, placebo-controlled, single blinded trial- Feasibility of FMT \[18 months\]\
- Safety: (serious) adverse events \[18 months\]32[NCT03439982](NCT03439982){#ir0355}I: FMT via colonoscopy + FMT via enemaSingle group, open label trial- Time to hepatic encephalopathy breakthrough \[9 weeks\]30[NCT03420482](NCT03420482){#ir0360}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, quadruple blinded trial- Psychometric Hepatic Encephalopathy Score \[28 days\]30[NCT03416751](NCT03416751){#ir0365}I: FMT via enema\
C: saline via enemaRandomized, placebo-controlled, double blinded trial- Safety: (serious) adverse events \[15 days\]\
- Related transmissible infectious disease \[15 days\]20[NCT02255617](NCT02255617){#ir0370}I: FMT via colonoscopy and enemaSingle group, open label trial- Time to hepatic encephalopathy breakthrough \[6 months\]10Acute Pancreatitis[NCT03015467](NCT03015467){#ir0375}I: FMT\
C: SalineRandomized, placebo-controlled, open label trial- Mortality \[3 months\]80[NCT02318134](NCT02318134){#ir0380}I: FMT via enema + traditional treatment\
C: traditional treatmentRandomized, controlled, single blinded trial- Gastrointestinal Failure score \[7--14 days\]60[NCT02318147](NCT02318147){#ir0385}I: FMT via enema + traditional treatment\
C: traditional treatmentRandomized, controlled, single blinded trial- Control of infectious complications \[from admission to discharge\]60Severe acute malnutrition[NCT03087097](NCT03087097){#ir0390}I: FMT via enema\
C: placebo via enemaRandomized, placebo-controlled, quadruple blinded trial- Safety: serious adverse events \[56 days\]20Anorexia Nervosa[NCT03928808](NCT03928808){#ir0395}I: FMT via DJSingle group, open label trial- Safety: (serious) adverse events \[30 days\]\
- Feasibility: participants recruited \[3 years\]\
- Tolerability: participants able to complete 4 FMT administrations \[3 years\]\
- Tolerability: GI distress Post FMT \[3 years\]10Graft Versus Host Disease[NCT03862079](NCT03862079){#ir0400}I: total gut decontamination + FMT via enema\
II: FMT via enema\
C: standard of care treatment3-arm, randomized, controlled, open label trial- Development of acute GVHD \[100 days\]\
- Relapse-free survival \[6 months\]120[NCT03678493](NCT03678493){#ir0405}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, open label trial- Incidence of infections \[4 months\]120[NCT03492502](NCT03492502){#ir0410}I: autologous FMT via DJSingle group, open label trial- Safety: (serious) adverse events \[7 days\]70[NCT03720392](NCT03720392){#ir0415}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, double blinded trial- Gut microbiome diversity \[1 month\]48[NCT03359980](NCT03359980){#ir0420}I: FMTSingle group, open label trial- GI and overall GVHD response \[28 days\]32[NCT03812705](NCT03812705){#ir0425}I: FMT via colonoscopy of ND tubeSingle group, open label trial- Response rate \[12 weeks\]30[NCT03549676](NCT03549676){#ir0430}I: FMT via DJSingle group, open label trial- Efficacy in the treatment of refractory GVHD on day 7 and 28.15[NCT03819803](NCT03819803){#ir0435}I: FMT via colonoscopySingle group, open label trial- GI-GVHD remission \[90 days\]15[NCT03214289](NCT03214289){#ir0440}I: FMT capsulesSingle group, open label trial- Safety: (serious) adverse events \[28 days\]4Cancer[NCT03819296](NCT03819296){#ir0445}I: FMTSingle group, open label trial- Safety: (serious) adverse events \[4 months\]\
- Incidence of toxicities \[1 year\]100[NCT03353402](NCT03353402){#ir0450}I: FMT via colonoscopy + FMT capsules with feces of responders to immunotherapySingle group, open label trial- Safety: (serious) adverse events \[4 years\]\
- Engraftment of fecal microbiota \[4 years\]40[NCT03341143](NCT03341143){#ir0455}I: FMT via colonoscopy + pembrolizumabSingle group, open label trial- Objective Response Rate \[3 years\]20Psoriatic arthritis[NCT03058900](NCT03058900){#ir0460}I: FMT via DJ + methotrexate\
C: saline via DJ + methotrexateRandomized, placebo-controlled, triple blinded trial- Treatment failure \[6 months\]80Rheumatoid arthritis[NCT03944096](NCT03944096){#ir0465}I: allogenic FMT via DJ + methotrexate\
C: autologous FMT + methotrexateRandomized, controlled, triple blinded trial- Clinical response (ACR20) \[16 weeks\]30Ankylosing Spondylitis[NCT03726645](NCT03726645){#ir0470}I: allogenic FMT\
C: autologous FMTRandomized, controlled, triple blinded trial- Clinical activity of ankylosing spondylitis \[12 months\]20Hepatitis B[NCT03429439](NCT03429439){#ir0475}I: FMT + antiviral therapy\
C: antiviral therapyRandomized, controlled, open label trial- Serum hepatitis B virus e antigen \[6 months\]60IgA Nephropathy[NCT03633864](NCT03633864){#ir0480}I: FMT via enemaSingle group, open label trial- Change of Urinary protein \[8 weeks\]30Recurrent urinary tract infection[NCT03050515](NCT03050515){#ir0485}I: FMT via enemaSingle group, open label trial- Frequency of culture proven urinary tract infections \[6 months\]12Peanut allergy[NCT02960074](NCT02960074){#ir0490}I: FMT capsulesSingle group, open label trial- Safety: (serious) adverse events \[12 months\]10Sjogren\'s syndrome[NCT03926286](NCT03926286){#ir0495}I: FMT via enemaSingle group, open label trial- Safety: (serious) adverse events \[7 months\]\
- Stable microbiome engraftment \[3 months\]10Parkinson\'s disease[NCT03876327](NCT03876327){#ir0500}I: FMT\
C: no interventionControlled, open label trial- Motor symptoms (UPDRS III) \[6 months\]\
- Constipation level \[6 months\]100[NCT03808389](NCT03808389){#ir0505}I: allogenic FMT via DJ\
C: autologous FMT via DJRandomized, controlled, quadruple blinded trial- Changes in clinical symptoms (MDS-UPDRS) \[12 months\]40[NCT03671785](NCT03671785){#ir0510}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, single blinded trial- Microbiome diversity in fecal Samples \[9 months\]\
- Microbiome Richness in Fecal Samples \[9 months\]\
- Safety: (serious) adverse events \[9 months\]12Multiple sclerosis[NCT03183869](NCT03183869){#ir0515}I: FMT\
C: no interventionRandomized, controlled, open label, crossover trial- Cytokines levels in peripheral blood \[6 months\]40[NCT03594487](NCT03594487){#ir0520}I: FMT via colonoscopy\
C: no interventionControlled, open label trial- Subjects who complete the study protocol \[1 year\]\
- Change in fecal microbiota \[12 weeks\]\
- Safety: (serious) adverse events \[12 weeks\]30Amyotrophic lateral sclerosis[NCT03766321](NCT03766321){#ir0525}I: FMT via DJ\
C: sham FMT via DJRandomized, placebo-controlled, quadruple blinded trial- Tregs number \[6 months\]42Depression[NCT03279224](NCT03279224){#ir0530}I: allogenic FMT via colonoscopy\
C: autologous FMT via colonoscopyRandomized, controlled, quadruple blinded trial- Depressive symptoms (MADRS) \[24 weeks\]60[NCT03281044](NCT03281044){#ir0535}I: FMT capsules\
C: placebo capsulesRandomized, placebo-controlled, triple blinded trial- Depressive symptoms (HRSD) \[8 months\]40[NCT03233100](NCT03233100){#ir0540}I: FMTSingle group, open label trial- Complete spontaneous bowl movements \[12 weeks\]\
- Anxiety symptoms (HAMA) \[12 weeks\]\
- Depressive symptoms (HAMD) \[12 weeks\]40Autism spectrum disorder[NCT03408886](NCT03408886){#ir0545}I: FMT capsules\
C: placebo capsulesRandomized, controlled, quadruple blinded trial- Autism symptoms CARS) \[10 weeks\]84[NCT03426826](NCT03426826){#ir0550}I: FMT via DJ\
C: placebo via DJRandomized, placebo-controlled, quadruple blinded trial- Safety and tolerability \[24 weeks\]\
- Symptom changes (RBS-R) \[24 weeks\]10Chronic fatigue syndrome[NCT03691987](NCT03691987){#ir0555}I: allogenic FMT via enema\
C: autologous FMT via enemaRandomized, controlled, quadruple blinded trial- Clinical response (FSS) \[3 months\]80Epilepsy[NCT02889627](NCT02889627){#ir0560}I: FMT via DJSingle group, open label trial- Frequency of the seizures \[3 months\]50[^2][^3]
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[^1]: The above disorders were only listed if there was at least a cohort study published. Abbreviations: RCT = randomized controlled trial, ESBL = extended-spectrum beta-lactamase, VRE = vancomycin-resistant *Enterococcus*, CRE = carbapenem-resistant *Enterobacteriaceae*, SCFA = short-chain fatty acid, HE = hepatic encephalopathy, SAE = serious adverse event \[[@bb0515]\].

[^2]: The above table summarizes ongoing trials studying the effect of FMT for a variety of diseases. Studies are grouped in 'gastrointestinal', 'metabolic', immunologic' and 'neuropsychiatric' disorders, sorted by disease and number of included patients. These studies were derived from [Clinicaltrial.gov](http://Clinicaltrial.gov){#ir0565} in May 2019. Ongoing trials were included when they were registered as 'Active', 'recruiting', 'enrolling via invitation' or 'not yet recruiting'. Only intervention studies were included. In addition, studies examining the effect of FMT in treating CDI were excluded, since this is out of the scope of this review. There were several methods for upper administration of FMT (i.e. gastroscopy, nasoduodenal tube, transendoscopic enteral tubing, etc.), which were pooled for simplicity as duodenal/jejunal infusion (DJ). Within brackets, the time frame of a primary outcome can be found. Abbreviations: I = intervention, C = control, FMT = fecal microbiota transplantation, DJ = duodenal/jejunal infusion, IBD = Inflammatory Bowel Disease, UC = Ulcerative Colitis, IBS = Irritable Bowel Syndrome, CRE = Carbapenem-Resistant Enterobacteriaceae, VRE = Vancomycin-Resistant Enterococci, ESBL-E = Extended Spectrum Beta-Lactamase Enterobacteriaceae, NAFLD = Non-Alcoholic Fatty Liver Disease, NASH = Non-Alcoholic Steatohepatitis, GI = Gastrointestinal, GVHD = Graft Versus Host Disease.

[^3]: Entry [NCT03582969](NCT03582969){#ir0570} was the same as [NCT03273465](NCT03273465){#ir0575}, which were therefore merged. The same goes for entry [NCT03477916](NCT03477916){#ir0580}, which was the same as [NCT03727321](NCT03727321){#ir0585}
